Overview

Suvorexant for Opioid/Stimulant Co-use

Status:
Not yet recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

Summary

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Treatments:

Orexin Receptor Antagonists
Suvorexant